Placebo + Lemborexant 10 mg + Placebo + Lemborexant 10 mg
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sleep Apnea, Obstructive
Conditions
Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders
Trial Timeline
Jan 6, 2021 → Feb 10, 2022
NCT ID
NCT04647383About Placebo + Lemborexant 10 mg + Placebo + Lemborexant 10 mg
Placebo + Lemborexant 10 mg + Placebo + Lemborexant 10 mg is a phase 1 stage product being developed by Eisai for Sleep Apnea, Obstructive. The current trial status is completed. This product is registered under clinical trial identifier NCT04647383. Target conditions include Sleep Apnea, Obstructive, Pulmonary Disease, Chronic Obstructive, Respiration Disorders.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04647383 | Phase 1 | Completed |
Competing Products
20 competing products in Sleep Apnea, Obstructive